Methods of device-assisted drug delivery
An active ingredient, a vasodilator technology, applied in the field of transdermal drug delivery, can solve problems such as limited capacity, and achieve the effects of increased speed, increased flexibility, improved efficiency and kinetics
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0026] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion (Lipomulse) 165 (2%) and cetyl alcohol (2%) at 40°C Stir for 30 minutes and mix well. Another container contained acrylic acid polymer (Pemulen) (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed at room temperature for about 20 minutes until homogeneous. 100 μg of recombinant human growth hormone was dissolved in (1%) physiological saline. Add somatotropin to the primary delivery vehicle formulation and mix well. A 1 g aliquot was taken into a container in a 1 cc 29 gauge injection needle device and injected into the subcutaneous tissue to be delivered.
Embodiment 2
[0028] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion 165 (2%) and cetyl alcohol (2%) were stirred at 40°C for 30 minutes and mix well. Another container contained acrylic acid polymer (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed for about 20 minutes at room temperature until homogeneous. 100 μg of recombinant human growth hormone was dissolved in (1%) physiological saline. Add somatotropin to the primary delivery vehicle formulation and mix well. Aliquots of 1 g are added to containers in microneedle devices designed to deliver substances in precise quantities. The device is brought into contact with the skin, and the pharmaceutical composition and the vasoactive drug delivery formulation carrier are administered simultaneou...
Embodiment 3
[0030] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion 165 (2%) and cetyl alcohol (2%) were stirred at 40°C for 30 minutes and mix well. Another container contained acrylic acid polymer (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed for about 20 minutes at room temperature until homogeneous. A separate formulation of the active drug molecule (eg 0.1% human insulin) is prepared, dissolved in (1%) saline and added to the drug delivery formulation in a separate and separate container in the delivery device. The drug formulations (0.1-2 g of each dosing vehicle) are applied to the reservoir of a microneedle device designed to deliver substances in precise quantities. The device is brought into contact with the skin, and the pharmaceu...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com